EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Thioparib inhibits homologous recombination repair, activates the type I IFN response, and overcomes olaparib resistance

Li-Min Wang iD, Pingyuan Wang, Xiao-Min Chen iD, Hui Yang iD, Shan-Shan Song, Zilan Song, Li Jia, Hua-Dong Chen iD, Xu-Bin Bao, Ne Guo iD, Xia-Juan Huan, Yong Xi und 11 weitere

EMBO Molecular Medicine · 2023

DOI: 10.15252/emmm.202216235 ↗

Kurz gefasst

Fachartikel in der Zeitschrift EMBO Molecular Medicine, 2023. Verfasst von Li-Min Wang und 22 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Drug Research, Cancer Research Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China. Hauptthemen laut MEDLINE: Interferon Type I, Neoplasms. Die Arbeit wurde bisher 46-mal zitiert (Crossref) und nennt 74 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: CAS ¦ State Key Laboratory of Drug Research, National Natural Science Foundation of China, SA‐SIBS Scholarship Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Poly‐ADP‐ribose polymerase (PARP) inhibitors (PARPi) have shown great promise for treating BRCA‐deficient tumors. However, over 40% of BRCA‐deficient patients fail to respond to PARPi. Here, we report that thioparib, a next‐generation PARPi with high affinity against multiple PARPs, including PARP1, PARP2, and PARP7, displays high antitumor activities against PARPi‐sensitive and ‐resistant cells with homologous recombination (HR) deficiency both in vitro and in vivo . Thioparib treatment elicited PARP1‐dependent DNA damage and replication stress, causing S‐phase arrest and apoptosis. Conversely, thioparib strongly inhibited HR‐mediated DNA repair while increasing RAD51 foci formation. Notably, the on‐target inhibition of PARP7 by thioparib‐activated STING/TBK1‐dependent phosphorylation of STAT1, triggered a strong induction of type I interferons (IFNs), and resulted in tumor growth retardation in an immunocompetent mouse model. However, the inhibitory effect of thioparib on tumor growth was more pronounced in PARP1 knockout mice, suggesting that a specific PARP7 inhibitor, rather than a pan inhibitor such as thioparib, would be more relevant for clinical applications. Finally, genome‐scale CRISPR screening identified PARP1 and MCRS1 as genes capable of modulating thioparib sensitivity. Taken together, thioparib, a next‐generation PARPi acting on both DNA damage response and antitumor immunity, serves as a therapeutic potential for treating hyperactive HR tumors, including those resistant to earlier‐generation PARPi.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Interferon Type INeoplasmsAnimalsMiceCell Line, TumorDNA RepairHomologous RecombinationPhthalazinesPoly(ADP-ribose) Polymerase InhibitorsRecombinational DNA RepairRNA-Binding ProteinsDrug Resistance, NeoplasmPiperazines

Stichwörter der Autor:innen

PARP inhibitorPARP7homologous recombination repairolaparib-resistanttype I interferons

Substanzen

Interferon Type IPhthalazinesPoly(ADP-ribose) Polymerase InhibitorsRNA-Binding ProteinsMcrs1 protein, mouseolaparibPiperazines

Autor:innen und Institutionen

  • State Key Laboratory of Drug Research, Cancer Research Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
  • University of Chinese Academy of Sciences, Beijing, China.
  • Pharm-X Center, School of Pharmacy, Shanghai Jiao Tong University, Shanghai, China.
  • Institute of Evolution and Marine Biodiversity, Ocean University of China, Qingdao, China.
  • The CAS Key Laboratory of Tissue Microenvironment and Tumor, Shanghai Institute of Nutrition and Health, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Shanghai, China.

ORCID-Profile: Li-Min Wang, Xiao-Min Chen, Hui Yang, Hua-Dong Chen, Ne Guo, Jing-Yu Lang, Ze-Hong Miao, Ao Zhang, Jin-Xue He

Förderung

  • CAS ¦ State Key Laboratory of Drug Research
  • National Natural Science Foundation of China
  • SA‐SIBS Scholarship Program
  • Science and Technology Commission of Shanghai Municipality
  • The Strategic Priority Research Program of the Chinese Academy of Sciences

Zitieren

APA

Wang, L. M., Wang, P., Chen, X. M., Yang, H., Song, S. S., Song, Z., Jia, L., Chen, H. D., Bao, X. B., Guo, N., Huan, X. J., Xi, Y., Shen, Y. Y., Yang, X. Y., Su, Y., Sun, Y. M., Gao, Y. L., Chen, Y., Ding, J., …, & He, J. X. (2023). Thioparib inhibits homologous recombination repair, activates the type I IFN response, and overcomes olaparib resistance. EMBO Molecular Medicine. https://doi.org/10.15252/emmm.202216235

Vancouver

Wang LM, Wang P, Chen XM, Yang H, Song SS, Song Z, et al. Thioparib inhibits homologous recombination repair, activates the type I IFN response, and overcomes olaparib resistance. EMBO Molecular Medicine. 2023. doi:10.15252/emmm.202216235

BibTeX
@article{Wang2023,
  author = {Wang, Li-Min and Wang, Pingyuan and Chen, Xiao-Min and Yang, Hui and Song, Shan-Shan and Song, Zilan and Jia, Li and Chen, Hua-Dong and Bao, Xu-Bin and Guo, Ne and Huan, Xia-Juan and Xi, Yong and Shen, Yan-Yan and Yang, Xin-Ying and Su, Yi and Sun, Yi-Ming and Gao, Ying-Lei and Chen, Yi and Ding, Jian and Lang, Jing-Yu and Miao, Ze-Hong and Zhang, Ao and He, Jin-Xue},
  title = {Thioparib inhibits homologous recombination repair, activates the type I IFN response, and overcomes olaparib resistance},
  journal = {EMBO Molecular Medicine},
  year = {2023},
  doi = {10.15252/emmm.202216235}
}
Kostenlos starten →